drugset
drugset / Trial / NCT02239081

A Safety and Tolerability Study of CTP-730 in Healthy Volunteers

NCT02239081 ↗

Phase 1 Completed 55 enrolled Concert Pharmaceuticals
RandomizedSingle-groupQuadruple-blindBasic science

Summary

This is a Phase 1, single center, single-ascending dose, randomized study

Timeline

Start
2014-09
Primary completion
2015-01
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject CTP-730 Unknown 5 mg Oral
Subject CTP-730 Unknown 10 mg Oral
Subject CTP-730 Unknown 20 mg Oral
Subject CTP-730 Unknown 30 mg Oral
Subject CTP-730 Unknown 40 mg Oral
Subject CTP-730 Unknown 50 mg Oral
Subject CTP-730 Unknown 60 mg Oral

Indications

No indication recorded.